Echinocandin B high-producing strain and application thereof

Abstract

The invention discloses an Echinocandin B high-producing strain which is a mutant strain of Aspergillus rugulovalvus ATCC 58398. The strain is collected in the General Microorganism Center of the China Committee for Culture Collection of Microorganisms and has the collection number of CGMCC (China General Microbiological Culture Collection Center) No. 5413. The invention also discloses application of the Echinocandin B high-producing strain. By using the obtained Echinocandin B high-producing strain, the yield of the prepared Echinocandin B reaches about 800 mg / l.

Description

technical field [0001] The invention belongs to the technical field of bioengineering, specifically, an echinocandin B high-yield bacterial strain and its application. Background technique [0002] In the past two decades, fungal infections that seriously endanger human life and health have been increasing in terms of mortality and types of infections, especially in immunosuppressed patients. The main drugs currently used to treat clinical deep fungal infections are azole antifungal drugs and amphotericin B. [0003] Although these two types of drugs have played an important role in controlling clinical deep fungal infections, the mortality rate of deep fungal infections remains high due to the following three deficiencies of these drugs: [0004] First, because the targets of these two types of drugs are fungal cell membranes, their selectivity is poor, resulting in relatively large toxic and side effects; [0005] The second is the reduced efficacy of these drugs due to ...

AI Technical Summary

Problems solved by technology

[0004] First, because the targets of these two types of drugs are fungal cell membranes, their selectivity is poor, resulting in relatively large toxic and side effects;

[0005] The second is the reduced efficacy of these drugs due to the widespread emergence of clinically resistant fungi;

[0006] The third is that these drugs are not very sensitive to fungi such as Aspergillus and Candida albicans, which makes it difficult to control the disease of this type of fungal infection clinically.

Due to the very low fermentation yield of echinocandin B, the yield of Anifungin was affected